Eptifibatide
Back to searchMolecule Structure
Scientific Name
Eptifibatide
Brand Name(s)
Eptifibatide, Integrilin
Company Owner(s)
Hainan Shuangcheng Pharmaceuticals Co Ltd, Mylan Laboratories Ltd, Sagent Pharmaceuticals Inc, Amneal Pharmaceuticals Of New York Llc, Eugia Pharma Specialities Ltd, Accord Healthcare Inc, Hybio Pharmaceutical Co Ltd, Teva Pharmaceuticals Usa, Hainan Poly Pharmaceutical Co Ltd, Merck Sharp And Dohme Llc A Sub Of Merck And Co Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Integrin alpha-IIb/beta-3 | PROTEIN COMPLEX | INHIBITOR | CHEMBL2093869 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL15781 | |
| PubChem: Thomson Pharma | 14889413 | 16531762 |
| PubChem | 448812 | |
| Mcule | MCULE-5698614065 | |
| Nikkaji | J1.559.018A | |
| BindingDB | 50092098 | |
| EPA CompTox Dashboard | DTXSID7046673 | |
| DrugCentral | 1040 | |
| ChemicalBook | CB0416566 | CB7416565 |
| Guide to Pharmacology | 6585 | |
| rxnorm | INTEGRILIN | EPTIFIBATIDE |
| PubChem: Drugs of the Future | 12014752 | |
| ChEBI | 291902 | |
| ZINC | ZINC000085536935 |
